Hospital
Ascension Ne Wisconsin, INC
Ascension Ne Wisconsin, INC was paid $4.31M by Medicaid between Jun 2020 and Dec 2024, across 183 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoASCENSION NE WISCONSIN, INC
OSHKOSH, WI 54904
OSHKOSH, WI 54904
33aNPI1912527193assigned 04/17/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.31M
24GClaims243,509
24DCodes billed183
24AFirst – last monthJun 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#28 of 60
Median peer was paid$2.90M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCULLOUGH, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 31,827 | $488K | |
| 2021 | 63,488 | $1.02M | |
| 2022 | 63,611 | $1.10M | |
| 2023 | 50,405 | $911K | |
| 2024incomplete | 34,178 | $796K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 7,766 | 6,634 | $482K |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 4,264 | 2,904 | $459K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.5% | 6,909 | 5,731 | $365K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.8% | 6,664 | 5,236 | $334K |
| 80053 | Comprehensive metabolic panel | 4.9% | 13,372 | 10,422 | $212K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,136 | 1,750 | $147K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 3.1% | 3,305 | 1,695 | $134K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 2,065 | 1,810 | $134K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 1,650 | 1,460 | $101K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 1,684 | 1,411 | $101K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.2% | 1,326 | 1,040 | $94K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 1,245 | 942 | $84K |
171 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.7% | 5,252 | $74K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 5,988 | $72K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 1,670 | $69K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.5% | 716 | $65K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 964 | $59K |
| 80061 | Lipid panel | 1.1% | 4,661 | $49K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 1,632 | $48K |
| G0378 | Hospital observation service, per hour | 1.1% | 1,697 | $48K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 939 | $46K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,872 | $43K |
| 87634 | <1% | 773 | $41K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,290 | $41K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,563 | $40K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 211 | $40K |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 4,461 | $37K |
| 80306 | <1% | 2,623 | $37K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,671 | $35K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 459 | $35K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,009 | $27K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,089 | $25K |
| 84484 | <1% | 2,885 | $25K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 335 | $23K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 334 | $22K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 396 | $22K |
| 81001 | <1% | 6,024 | $22K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,065 | $20K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 601 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,540 | $19K |
| 0240U | <1% | 470 | $15K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,150 | $15K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 237 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,012 | $14K |
| 83690 | <1% | 2,864 | $14K | |
| 86803 | <1% | 1,192 | $14K | |
| 81025 | <1% | 1,567 | $14K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,000 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 968 | $13K |
| 85027 | <1% | 3,102 | $12K | |
| 85610 | <1% | 3,296 | $12K | |
| 82728 | <1% | 957 | $11K | |
| 84703 | <1% | 1,725 | $11K | |
| 84439 | <1% | 1,237 | $11K | |
| 83735 | <1% | 2,314 | $10K | |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | <1% | 549 | $10K |
| 82947 | <1% | 1,097 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 549 | $10K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 124 | $10K |
| 99001 | <1% | 1,597 | $10K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 548 | $9K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 536 | $8K |
| 80143 | <1% | 722 | $8K | |
| 83880 | <1% | 423 | $8K | |
| 86780 | <1% | 850 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,698 | $8K |
| 82962 | <1% | 929 | $8K | |
| 82607 | <1% | 645 | $7K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 112 | $7K |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | <1% | 1,218 | $7K |
| 80179 | <1% | 688 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 358 | $7K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 1,041 | $7K |
| 74018 | <1% | 402 | $6K | |
| 87070 | <1% | 949 | $6K | |
| 82077 | <1% | 781 | $6K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 205 | $6K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 247 | $6K |
| 86140 | <1% | 1,474 | $6K | |
| 87340 | <1% | 793 | $6K | |
| 83605 | <1% | 760 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 505 | $6K |
| 80076 | <1% | 643 | $6K | |
| 87081 | <1% | 578 | $6K | |
| 84702 | <1% | 330 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 77 | $5K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 375 | $5K |
| 87653 | <1% | 164 | $5K | |
| 85379 | <1% | 725 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 63 | $5K |
| 85007 | <1% | 1,224 | $5K | |
| 87077 | <1% | 485 | $5K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 127 | $4K |
| 82565 | <1% | 599 | $4K | |
| 87186 | <1% | 680 | $4K | |
| 87210 | <1% | 747 | $4K | |
| 84153 | <1% | 290 | $4K | |
| 84481 | <1% | 344 | $4K | |
| 86850 | <1% | 945 | $4K | |
| 84450 | <1% | 599 | $4K | |
| 83550 | <1% | 597 | $4K | |
| 83655 | <1% | 305 | $3K | |
| 83540 | <1% | 778 | $3K | |
| 82043 | <1% | 714 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,010 | $3K |
| 82950 | <1% | 259 | $3K | |
| 86762 | <1% | 279 | $3K | |
| 87205 | <1% | 938 | $3K | |
| 86900 | <1% | 942 | $3K | |
| 84460 | <1% | 816 | $3K | |
| 85730 | <1% | 880 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 55 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,244 | $2K |
| 94729 | <1% | 139 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,638 | $2K |
| 86901 | <1% | 939 | $2K | |
| 73564 | <1% | 160 | $2K | |
| 86787 | <1% | 304 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 279 | $2K |
| 73030 | <1% | 128 | $2K | |
| 83970 | <1% | 66 | $2K | |
| 97162 | <1% | 37 | $1K | |
| 82465 | <1% | 142 | $1K | |
| 85652 | <1% | 772 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 20 | $1K |
| 94726 | <1% | 139 | $1K | |
| 81003 | <1% | 433 | $1K | |
| 85018 | <1% | 372 | $1K | |
| 93975 | <1% | 21 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,470 | $1K |
| 84466 | <1% | 106 | $948.59 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,515 | $911.64 |
| 94060 | <1% | 30 | $906.63 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 460 | $896.92 |
| 82550 | <1% | 207 | $886.32 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $800.69 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 254 | $665.18 |
| 93017 | <1% | 12 | $641.80 | |
| 97597 | <1% | 21 | $491.92 | |
| 83718 | <1% | 64 | $457.53 | |
| 84100 | <1% | 119 | $449.55 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 19 | $445.99 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,141 | $413.08 |
| 96376 | <1% | 1,037 | $400.61 | |
| 93226 | <1% | 19 | $398.39 | |
| 73610 | <1% | 95 | $353.63 | |
| 84145 | <1% | 23 | $348.19 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,673 | $341.99 |
| 86038 | <1% | 32 | $318.21 | |
| 73502 | <1% | 12 | $299.36 | |
| 82746 | <1% | 15 | $192.04 | |
| 87147 | <1% | 53 | $172.48 | |
| 73110 | <1% | 33 | $171.46 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,215 | $170.19 |
| 90715 | <1% | 29 | $169.50 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,162 | $125.81 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $116.38 |
| 94200 | <1% | 31 | $109.86 | |
| 84550 | <1% | 26 | $102.17 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 70 | $96.96 |
| 82040 | <1% | 28 | $91.08 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,401 | $84.52 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,708 | $79.55 |
| 73630 | <1% | 94 | $78.20 | |
| 82247 | <1% | 23 | $75.26 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 16 | $57.44 |
| 82570 | <1% | 14 | $56.13 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,582 | $44.24 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,426 | $44.18 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,522 | $40.44 |
| 84156 | <1% | 13 | $39.51 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 215 | $38.47 |
| 73130 | <1% | 29 | $20.13 | |
| A9270 | Non-covered item or service | <1% | 4,402 | $14.19 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 385 | $4.62 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 880 | $3.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,301 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 45 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 212 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 706 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 38 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 65 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCULLOUGH, MICHAEL (CFO)
Parent organizationASCENSION NE WISCONSIN, INC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.